MétaCan
Menu
← Back to cohort
Record W7117247930 · doi:10.1002/alz70859_099279

Tau positron emission tomography results from TOGETHER, a double‐blind, placebo‐controlled Phase II study of bepranemab in prodromal–mild Alzheimer’s disease

2025· article· en· W7117247930 on OpenAlexaff
R. P. Maguire, William Byrnes, Matthew E. Barton, Irene Rebollo Mesa, Tim Buchanan, Bart Van Den Steen, Hans Lieve G. Van Tricht, Katie Taiyari, Omobola Famodimu, Jos Bloemers, Steve Einstein, Colin Ewen

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsGeotab (Canada)
Fundersnot available
KeywordsPositron emission tomographyPhase (matter)Antibody therapyDiseaseBrain positron emission tomography

Abstract

fetched live from OpenAlex

BACKGROUND: Bepranemab is a recombinant, humanized, full-length immunoglobulin G4 monoclonal antibody that targets a mid-region epitope of human tau. TOGETHER (NCT04867616), a Phase II participant- and investigator-blinded, randomized, placebo-controlled study, assessed efficacy and safety of bepranemab in people with prodromal-mild Alzheimer's disease (AD). Previously presented data from TOGETHER indicate a clinical benefit with bepranemab. Here, we describe the effect of bepranemab on tau accumulation in the brain in study participants with prodromal or mild AD. METHODS: F] Genentech tau probe 1 (GTP1) and underwent positron emission tomography (PET) imaging at Baseline, Week 56, and Week 80. Eligibility criteria included prodromal-mild AD (National Institute on Aging and the Alzheimer's Association 2018 Stage 3/4); cerebral amyloid beta presence (PET or cerebrospinal fluid); global Clinical Dementia Rating (CDR) score of 0.5; CDR-Memory Box score ≥0.5. Secondary objectives included investigating the effect of bepranemab on tau-PET imaging at Weeks 56 and 80. PET images were analyzed by a central imaging laboratory to determine the standardized uptake value ratio relative to cerebellum in multiple brain regions. RESULTS: In total, 466 participants were randomized 1:1:1 across three arms (90 mg/kg bepranemab, 45 mg/kg bepranemab, placebo). Bepranemab slowed tau accumulation (by 33-58% vs placebo, across both bepranemab arms) in the whole cortical gray (n=scanned/total: 90 mg/kg bepranemab [n=113/152], 45 mg/kg bepranemab [n=104/152], and placebo [n=97/156]) and jack temporal meta regions (n=scanned/total: 90 mg/kg bepranemab [n=114/152], 45 mg/kg bepranemab [n=105/152], and placebo [n=97/156]) at Week 80 in the initial analysis of the full trial population (those who received at least a partial dose of study medication and had at least one valid post-Baseline clinic visit and efficacy assessment). Data on tau accumulation in regions based on Braak staging will be presented. CONCLUSION: TOGETHER provides the first clinical demonstration of slowing of tau accumulation with an antibody targeting the tau mid-region, as evidenced by tau PET imaging, and marks the first time that any tau-directed therapy has demonstrated a clinical benefit.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.353
Teacher spread0.312 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→